Resources

BENSON CAPITAL PARTNERS ANNOUNCES FIRST INVESTMENT IN AXOSIM, INC. AxoSim, Inc, Provider of BrainSim™ and NerveSim™ Neurological Drug Discovery Platforms Teams with Benson Capital Partners and Jefferson Capital Partners For Immediate Release: November 5, 2020 […]

October 30, 2020 –Two grants from the DoD Congressionally Directed Medical Research Program and the National Institutes of Health awarded to AxoSim–  –The CDMRP grant will support the development of a ALS NerveSim™ model to […]

AxoSim Scientist, Wesley Anderson, will be a Rapid Fire speaker at the 2020 AAPS PharmSci 360 Conference on Tuesday, November 3rd at 9:30am EST.  His presentation is titled Development and Qualification of a Novel In […]

On Wednesday, September 30th, AxoSim Lead Scientist, Anup Sharma, PhD, spoke at our interactive webinar: Human Schwann Cells: Importance for Peripheral Neuropathy Preclinical Research. During this webinar, Dr. Sharma spoke about AxoSim’s Human Peripheral Co-Culture […]

High Throughput, Human Data: AxoSim’s Human Peripheral Co-Culture Assay In addition to our 3D NerveSim™ and BrainSim™ models, AxoSim also performs a variety of cell-based 2D assays including our new Human Schwann Cell and iPSC-derived […]

Introducing our newest SimLab Service: Human Co-Culture Peripheral Assay We are excited to launch our newest assay which uses human Schwann cells and iPSC-derived neurons to recapitulate the results one can expect to see from […]

On Wednesday, September 16th at 11:00am EST, AxoSim CEO, Dr. Lowry Curley will be giving a dynamic poster presentation at Safety Pharmacology Society’s (SPS) Annual Meeting, held virtually this year.  The poster, #026, is entitled […]

Over 90% of neurological drugs that are successfully tested in animals fail once they reach human clinical trials. Therefore, there is a need for new, clinically relevant, preclinical testing models that mimic the human nervous […]

February 21. 2020 Selective serotonin reuptake inhibitors (SSRIs) are frequently used to treat depression during pregnancy. Various concerns have been raised about the possible effects of these drugs on fetal development. Current developmental neurotoxicity (DNT) […]

July 15, 2020 Organ-on-a-chip devices that mimic in vivo physiology have the potential to identify effects of chemical and drug exposure in early preclinical stages of drug development while relying less heavily on animal models. We designed […]